Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study
Background The cholinesterase inhibitor donepezil is used to treat mild-to-moderate Alzheimer's disease. Its efficacy in severe dementia has not been assessed and is controversial. Our aim was to ascertain the effectiveness of donepezil in patients with severe Alzheimer's disease, by focusing primarily on cognition and activities of daily living. Methods We did a 6-month, double-blind, parallel-gr